Changes in striatal dopamine release and locomotor activity following acute withdrawal from chronic nicotine are mediated by CRF1, but not CRF2, receptors

András Buzás, Péter Bokor, Beáta Balangó, Dávid Pintér, Miklós Palotai, Balázs Simon, Krisztina Csabafi, G. Telegdy, Gyula Szabó, Zsolt Bagosi

Research output: Contribution to journalArticle

Abstract

The aim of the present study was to investigate the participation of corticotropin-releasing factor (CRF) receptors (CRF1 and CRF2) in the alterations of the dorsal and ventral striatal dopamine release and the vertical and horizontal locomotor activity observed in rats following chronic nicotine treatment and consequent acute withdrawal. In this purpose, male Wistar rats were exposed to repeated intraperitoneal (ip) injection with nicotine or saline solution for 7 days. On the 8th day or the 9th day the rats were injected intracerebroventricularly (icv) with selective CRF1 antagonist antalarmin or selective CRF2 antagonist astressin2B or saline solution. Thirty minutes after the icv injection the changes of the horizontal and vertical locomotor activity were recorded in an in vivo conducta system. Immediately after the behavioral recordings the changes of the dorsal and ventral striatal dopamine release were determined in an in vitro superfusion system. On the 8th day, the horizontal and vertical locomotor activities and the dorsal and ventral striatal dopamine releases increased significantly in nicotine-treated rats, compared to the saline-treated ones. On the 9th day, the horizontal locomotor activity and the dorsal striatal dopamine release increased significantly, whereas the vertical locomotor activity and the ventral striatal dopamine release decreased significantly in nicotine-treated rats, compared to the saline-treated ones. All the changes observed were attenuated significantly by antalarmin, but not astressin2B. The present study demonstrates that the changes of striatal dopamine release and locomotor activity observed following chronic nicotine treatment and consequent acute withdrawal are mediated by CRF1, but not CRF2, receptor.

LanguageEnglish
Pages41-47
Number of pages7
JournalBrain research
Volume1706
DOIs
Publication statusPublished - Mar 1 2019

Fingerprint

Corticotropin-Releasing Hormone Receptors
Corpus Striatum
Locomotion
Nicotine
Dopamine
Sodium Chloride
Intraperitoneal Injections
CRF receptor type 2
Wistar Rats
Injections
Therapeutics

Keywords

  • CRF receptor
  • Locomotor activity
  • Nicotine
  • Rats
  • Striatal dopamine release

ASJC Scopus subject areas

  • Neuroscience(all)
  • Molecular Biology
  • Clinical Neurology
  • Developmental Biology

Cite this

Changes in striatal dopamine release and locomotor activity following acute withdrawal from chronic nicotine are mediated by CRF1, but not CRF2, receptors. / Buzás, András; Bokor, Péter; Balangó, Beáta; Pintér, Dávid; Palotai, Miklós; Simon, Balázs; Csabafi, Krisztina; Telegdy, G.; Szabó, Gyula; Bagosi, Zsolt.

In: Brain research, Vol. 1706, 01.03.2019, p. 41-47.

Research output: Contribution to journalArticle

Buzás, András ; Bokor, Péter ; Balangó, Beáta ; Pintér, Dávid ; Palotai, Miklós ; Simon, Balázs ; Csabafi, Krisztina ; Telegdy, G. ; Szabó, Gyula ; Bagosi, Zsolt. / Changes in striatal dopamine release and locomotor activity following acute withdrawal from chronic nicotine are mediated by CRF1, but not CRF2, receptors. In: Brain research. 2019 ; Vol. 1706. pp. 41-47.
@article{9cbad59a1c714fca94bdd36f24f6ce0f,
title = "Changes in striatal dopamine release and locomotor activity following acute withdrawal from chronic nicotine are mediated by CRF1, but not CRF2, receptors",
abstract = "The aim of the present study was to investigate the participation of corticotropin-releasing factor (CRF) receptors (CRF1 and CRF2) in the alterations of the dorsal and ventral striatal dopamine release and the vertical and horizontal locomotor activity observed in rats following chronic nicotine treatment and consequent acute withdrawal. In this purpose, male Wistar rats were exposed to repeated intraperitoneal (ip) injection with nicotine or saline solution for 7 days. On the 8th day or the 9th day the rats were injected intracerebroventricularly (icv) with selective CRF1 antagonist antalarmin or selective CRF2 antagonist astressin2B or saline solution. Thirty minutes after the icv injection the changes of the horizontal and vertical locomotor activity were recorded in an in vivo conducta system. Immediately after the behavioral recordings the changes of the dorsal and ventral striatal dopamine release were determined in an in vitro superfusion system. On the 8th day, the horizontal and vertical locomotor activities and the dorsal and ventral striatal dopamine releases increased significantly in nicotine-treated rats, compared to the saline-treated ones. On the 9th day, the horizontal locomotor activity and the dorsal striatal dopamine release increased significantly, whereas the vertical locomotor activity and the ventral striatal dopamine release decreased significantly in nicotine-treated rats, compared to the saline-treated ones. All the changes observed were attenuated significantly by antalarmin, but not astressin2B. The present study demonstrates that the changes of striatal dopamine release and locomotor activity observed following chronic nicotine treatment and consequent acute withdrawal are mediated by CRF1, but not CRF2, receptor.",
keywords = "CRF receptor, Locomotor activity, Nicotine, Rats, Striatal dopamine release",
author = "Andr{\'a}s Buz{\'a}s and P{\'e}ter Bokor and Be{\'a}ta Balang{\'o} and D{\'a}vid Pint{\'e}r and Mikl{\'o}s Palotai and Bal{\'a}zs Simon and Krisztina Csabafi and G. Telegdy and Gyula Szab{\'o} and Zsolt Bagosi",
year = "2019",
month = "3",
day = "1",
doi = "10.1016/j.brainres.2018.10.028",
language = "English",
volume = "1706",
pages = "41--47",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",

}

TY - JOUR

T1 - Changes in striatal dopamine release and locomotor activity following acute withdrawal from chronic nicotine are mediated by CRF1, but not CRF2, receptors

AU - Buzás, András

AU - Bokor, Péter

AU - Balangó, Beáta

AU - Pintér, Dávid

AU - Palotai, Miklós

AU - Simon, Balázs

AU - Csabafi, Krisztina

AU - Telegdy, G.

AU - Szabó, Gyula

AU - Bagosi, Zsolt

PY - 2019/3/1

Y1 - 2019/3/1

N2 - The aim of the present study was to investigate the participation of corticotropin-releasing factor (CRF) receptors (CRF1 and CRF2) in the alterations of the dorsal and ventral striatal dopamine release and the vertical and horizontal locomotor activity observed in rats following chronic nicotine treatment and consequent acute withdrawal. In this purpose, male Wistar rats were exposed to repeated intraperitoneal (ip) injection with nicotine or saline solution for 7 days. On the 8th day or the 9th day the rats were injected intracerebroventricularly (icv) with selective CRF1 antagonist antalarmin or selective CRF2 antagonist astressin2B or saline solution. Thirty minutes after the icv injection the changes of the horizontal and vertical locomotor activity were recorded in an in vivo conducta system. Immediately after the behavioral recordings the changes of the dorsal and ventral striatal dopamine release were determined in an in vitro superfusion system. On the 8th day, the horizontal and vertical locomotor activities and the dorsal and ventral striatal dopamine releases increased significantly in nicotine-treated rats, compared to the saline-treated ones. On the 9th day, the horizontal locomotor activity and the dorsal striatal dopamine release increased significantly, whereas the vertical locomotor activity and the ventral striatal dopamine release decreased significantly in nicotine-treated rats, compared to the saline-treated ones. All the changes observed were attenuated significantly by antalarmin, but not astressin2B. The present study demonstrates that the changes of striatal dopamine release and locomotor activity observed following chronic nicotine treatment and consequent acute withdrawal are mediated by CRF1, but not CRF2, receptor.

AB - The aim of the present study was to investigate the participation of corticotropin-releasing factor (CRF) receptors (CRF1 and CRF2) in the alterations of the dorsal and ventral striatal dopamine release and the vertical and horizontal locomotor activity observed in rats following chronic nicotine treatment and consequent acute withdrawal. In this purpose, male Wistar rats were exposed to repeated intraperitoneal (ip) injection with nicotine or saline solution for 7 days. On the 8th day or the 9th day the rats were injected intracerebroventricularly (icv) with selective CRF1 antagonist antalarmin or selective CRF2 antagonist astressin2B or saline solution. Thirty minutes after the icv injection the changes of the horizontal and vertical locomotor activity were recorded in an in vivo conducta system. Immediately after the behavioral recordings the changes of the dorsal and ventral striatal dopamine release were determined in an in vitro superfusion system. On the 8th day, the horizontal and vertical locomotor activities and the dorsal and ventral striatal dopamine releases increased significantly in nicotine-treated rats, compared to the saline-treated ones. On the 9th day, the horizontal locomotor activity and the dorsal striatal dopamine release increased significantly, whereas the vertical locomotor activity and the ventral striatal dopamine release decreased significantly in nicotine-treated rats, compared to the saline-treated ones. All the changes observed were attenuated significantly by antalarmin, but not astressin2B. The present study demonstrates that the changes of striatal dopamine release and locomotor activity observed following chronic nicotine treatment and consequent acute withdrawal are mediated by CRF1, but not CRF2, receptor.

KW - CRF receptor

KW - Locomotor activity

KW - Nicotine

KW - Rats

KW - Striatal dopamine release

UR - http://www.scopus.com/inward/record.url?scp=85055626190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055626190&partnerID=8YFLogxK

U2 - 10.1016/j.brainres.2018.10.028

DO - 10.1016/j.brainres.2018.10.028

M3 - Article

VL - 1706

SP - 41

EP - 47

JO - Brain Research

T2 - Brain Research

JF - Brain Research

SN - 0006-8993

ER -